The U.S. Food and Drug Administration has approved Sanofi‘s Admelog, which is the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime.   “Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes. Complementing our existing insulin portfolio, Admelog will offer a more affordable option for those who require control of their blood sugar levels at mealtime,” said Stefan Oelr...